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ABSTRACT The potential for microbes to overcome antibiotics of different classes
before they reach bacterial cells is largely unexplored. Here we show that a soluble
bacterial lipocalin produced by Burkholderia cenocepacia upon exposure to sublethal
antibiotic concentrations increases resistance to diverse antibiotics in vitro and in
vivo. These phenotypes were recapitulated by heterologous expression in B. cenoce-
pacia of lipocalin genes from Pseudomonas aeruginosa, Mycobacterium tuberculosis,
and methicillin-resistant Staphylococcus aureus. Puriﬁed lipocalin bound different
classes of bactericidal antibiotics and contributed to bacterial survival in vivo. Experi-
mental and X-ray crystal structure-guided computational studies revealed that li-
pocalins counteract antibiotic action by capturing antibiotics in the extracellular
space. We also demonstrated that fat-soluble vitamins prevent antibiotic capture by
binding bacterial lipocalin with higher afﬁnity than antibiotics. Therefore, bacterial li-
pocalins contribute to antimicrobial resistance by capturing diverse antibiotics in the
extracellular space at the site of infection, which can be counteracted by known vi-
tamins.
IMPORTANCE Current research on antibiotic action and resistance focuses on tar-
geting essential functions within bacterial cells. We discovered a previously unrecog-
nized mode of general bacterial antibiotic resistance operating in the extracellular
space, which depends on bacterial protein molecules called lipocalins. These mole-
cules are highly conserved in most bacteria and have the ability to capture different
classes of antibiotics outside bacterial cells. We also discovered that liposoluble vita-
mins, such as vitamin E, overcome in vitro and in vivo antibiotic resistance mediated
by bacterial lipocalins, providing an unexpected new alternative to combat resis-
tance by using this vitamin or its derivatives as antibiotic adjuvants.
Treating infections is becoming increasingly difﬁcult since microbes often showintrinsic high-level resistance to virtually all clinically approved antibiotics (1).
Ineffective microbial killing and exposure to sublethal antibiotic concentrations elicit
adaptive bacterial stress responses, enhancing antibiotic resistance and tolerance (2–7).
Much has been learned about antibiotic resistance mechanisms at the cellular level (8,
9), but whether microbes subvert the action of antibiotics before they come in contact
with bacterial cells has remained largely unexplored, with the exception of
-lactamases, which are often trapped in released membrane vesicles (10–13), and the
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recent observation that Staphylococcus aureus inactivates daptomycin by releasing
membrane phospholipids (14).
Burkholderia cenocepacia is a highly multidrug resistant, opportunistic, Gram-
negative bacterium that causes serious respiratory infections in patients with cystic
ﬁbrosis (15). Bacteria of the genus Burkholderia are notorious for their ability to resist
the action of multiple classes of antimicrobials (16), representing an attractive model to
understand intrinsic mechanisms of resistance in opportunistic bacteria. Recently, we
showed that in response to sublethal antibiotic concentrations, B. cenocepacia pro-
duces and releases molecules such as the polyamine putrescine and YceI, a conserved
hypothetical protein of unknown function (17). YceI proteins are a family of bacterial
lipocalins (BCNs), which are small proteins widely conserved in Gram-negative and
Gram-positive bacteria but whose physiological role is unclear (18, 19). In coculture
experiments, B. cenocepacia protects Pseudomonas aeruginosa from killing by different
bactericidal antibiotics (17). This effect was abrogated in the B. cenocepacia ΔbcnA-bcnB
double-deletion mutant (17), but the individual contribution of each BCN paralog and
its mechanism remained unknown.
Here, we show that secreted BcnA contributes to increased resistance of B. cenoce-
pacia to various classes of antibiotics in vitro and in vivo. The expression of BCN
orthologs from P. aeruginosa, Mycobacterium tuberculosis, and methicillin-resistant
S. aureus in a B. cenocepacia ΔbcnA mutant recapitulated this function. Experimental
and computational studies revealed that BCNs bind to a range of antibiotics, thus
preventing their antibacterial activity and contributing to resistance. X-ray crystallog-
raphy studies of BCN structures, in combination with docking and MD simulations, have
helped us to rationalize plausible binding modes. We also discovered that fat-soluble
vitamins bound BcnA with a higher afﬁnity than antibiotics, enabling them to outcom-
pete antibiotics. This ﬁnding provides a clinically applicable strategy whereby known
vitamins could become antibiotic adjuvants by increasing the concentration of free
antibiotics in the proximity of bacterial cells, thereby boosting their microbicidal
activity.
RESULTS
BcnA is a secreted bacterial lipocalin required for full resistance of B. cenoce-
pacia to different classes of antibiotics. We investigated the role of B. cenocepacia
BcnA (BCAL3311) and BcnB (BCAL3310) by constructing individual deletion mutants in
their corresponding genes and assessing bacterial susceptibility to model bactericidal
antibiotics representing different classes, including rifamycins (mRNA transcription
inhibitors), ﬂuoroquinolones (DNA replication inhibitors), several -lactams (cell wall
peptidoglycan synthesis inhibitors), and cationic antimicrobial peptides (cell membrane
active agents). The ΔbcnA mutant, but not the ΔbcnB mutant, had increased suscepti-
bility (4-fold MIC reduction) to rifampin, norﬂoxacin, ceftazidime, and the cationic
antimicrobial peptide polymyxin B (PmB) and a 2-fold meropenem MIC reduction. No
effect was observed with the aminoglycoside gentamicin (protein synthesis inhibitor)
(Fig. 1A; see antibiotic chemical structures in Fig. S1 in the supplemental material).
Similarly, we also tested model bacteriostatic antibiotics representing different classes.
The ΔbcnA mutant, but not the ΔbcnB mutant, had increased susceptibility to mino-
cycline (tetracycline family protein synthesis inhibitor; 4-fold MIC reduction) and trim-
ethoprim (pyrimidine inhibitor of bacterial dihydrofolate reductase; 2-fold MIC reduc-
tion), while no effect was observed with the macrolide (protein synthesis inhibitor)
azithromycin (Fig. 1A; see Fig. S1).
The expression of the bcnA and bcnB genes in response to antibiotics at concen-
trations near the MIC (sublethal) was characterized by constructing chromosomal lux
fusions. Expression of bcnA::luxCDABE was upregulated upon exposure to PmB, rifam-
pin, norﬂoxacin, and ceftazidime (Fig. 1B). In contrast, bcnA::luxCDABE expression in
response to gentamicin remained unchanged (Fig. 1B). Expression of bcnB::luxCDABE
only increased upon exposure to norﬂoxacin and ceftazidime (Fig. S2A). Thus, the bcnA
and bcnB genes respond to antibiotic stress, but they appeared to be differentially
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regulated. bcnA and bcnB are located on the same strand 63 bp apart (Fig. 1C).
Immediately upstream of bcnA, there is an open reading frame (BCAL3312), also
transcribed on the same strand, that encodes a predicted cytochrome b651 protein.
Putative promoter regions are found upstream of BCAL3312 and downstream from
bcnB, next to a predicted Rho-independent transcription termination sequence. The
genomic organization of the bcn region suggests that BCAL3312, bcnA, and bcnB are
cotranscribed and may form an operon. However, the transcribed 63-bp intergenic
region between bcnA and bcnB has the potential to form strong RNA secondary
structures, which might explain the differential regulation of the two genes by antibi-
otics. The secretion of the BcnA and BcnB proteins was also investigated by using
FLAG-tagged derivatives; only BcnA was secreted extracellularly into the growth me-
dium (Fig. S2B). From these experiments, we concluded that BcnA is the major
contributor to intrinsic antibiotic resistance upon antibiotic stress and is secreted into
the extracellular bacterial milieu.
BCN orthologs from different species restore BcnA function in B. cenocepacia.
To demonstrate whether BCN orthologs from other bacteria could restore BcnA func-
tion in the ΔbcnA mutant strain, we tested BCNs of P. aeruginosa PAO1 [PA0423,
FIG 1 B. cenocepacia BcnA confers resistance to hydrophobic but not hydrophilic antibiotics. (A) MICs
of different antibiotics determined by broth microdilution in cation-adjusted MHB at 18 to 24 h
(representative of three independent experiments). (B) Luciferase expression assay of B. cenocepacia
BcnA (OME61) in response to antibiotics at 3 h (n  6 from two different clones). Results are shown as
the mean number of relative light units (RLU)/OD600 unit  SEM. The percent OD600 values are shown
in Fig. S2D. *, P  0.05; **, P  0.01; ***, P  0.001 (from one-way ANOVA [overall P  0.001] and the
Bonferroni post hoc test comparing against the non-antibiotic-treated control conditions). At the chosen
sample size, the actual power of the assay to detect signiﬁcant effects at a signiﬁcance level (alpha) of
0.05, two tailed, is 99% in the case of PmB and Rif and 90% for the rest of the conditions. ns, not
signiﬁcant. (C) Genomic organization of the B. cenocepacia K56-2 region. The asterisk indicates that the
transcribed intergenic sequence between bcnA and bcnB has the potential to form strong secondary
structures, as determined with Mfold (http://unafold.rna.albany.edu/?qmfold/download-mfold) (71).
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PA4340, and PA4345, which are BcnA1(Pa), BcnA2(Pa), and BcnA3(Pa), respectively,
here], M. tuberculosis H37Rv [Rv1890c, which is BcnA(MTb) here], and community-
acquired methicillin-resistant S. aureus USA300 [SAUSA300_2620, which is BcnA(Sa)
here]. CFU counts on PmB-containing plates (Fig. 2A) and E-test MICs of rifampin,
ceftazidime, and ciproﬂoxacin (a ﬂuoroquinolone closely related to norﬂoxacin) (Fig. 2B)
showed that heterologous expression of BCNs from these different bacteria restores
antibiotic resistance to parental levels, indicating that these proteins have a conserved
function.
BcnA sequesters antibiotics. BCNs bind to diverse hydrophobic molecules (20–22);
hence, we hypothesized that BCNs could capture antibiotics and reduce their effective
concentration in the bacterial milieu. An antibiotic bioassay demonstrated that BcnA
sequestered rifampin, PmB, norﬂoxacin, and ceftazidime, in descending order of mag-
nitude, but not gentamicin (Fig. 3A; see Fig. S3A to E). Further, the relative afﬁnity of
BcnA for antibiotics was determined in vitro by binding competition of antibiotics with
Nile red in complex with BcnA. Nile red is a ﬂuorophore used to test hydrophobic
binding sites in proteins (23). The calculated binding inhibitory constants (Ki values) of
the antibiotics (Fig. 3B; see Fig. S3F to M) mirrored their relative abilities to be
sequestered by BcnA (Fig. 3A) and the antibiotic susceptibility phenotypes of the ΔbcnA
mutant (Fig. 1A). Notably, the binding of BcnB to Nile red occurred with ~20-fold lower
afﬁnity than that of BcnA (Fig. S3N to Q), agreeing with the lesser role of BcnB in
antibiotic resistance. The involvement of hydrophobic moieties in the interaction of
ligands with BcnA was suggested by the signiﬁcantly higher Ki value of the PmB
nonapeptide, which lacks the hydrophobic N-terminal tail of PmB (24), relative to that
of PmB (Fig. 3B; see Fig. S3F to I). Notably, azithromycin and gentamicin, the only
antibiotics not showing the antibiotic sensitivity reduction phenotype with the ΔbcnA
FIG 2 BCNs from different bacteria can restore the B. cenocepacia ΔbcnA mutant to full antibiotic
resistance. (A) Mean CFU count  SEM on LB agar containing PmB from three independent experiments
(n  6; asterisks denote differences from the ΔbcnA/pSCRhaB2 mutant). *, P  0.05; **, P  0.01; ***, P 
0.001 (determined by two-way ANOVA and the Bonferroni post hoc test on the log CFU-per-milliliter
values with an overall P value of 0.001 for variations across the different mutants and because of
different concentrations). At the chosen sample size, the actual power of the assay to detect statistically
signiﬁcant effects at a signiﬁcance level (alpha) of 0.05, two tailed, ranged between 85 and99% for the
different mutants tested. (B) MICs of rifampin (Rif), ceftazidime (Cef), and ciproﬂoxacin (Cipro) determined
by E test in a representative of three independent experiments. The highest rifampin concentration on
the E-test strips is 32 g/ml; 64 indicates that an MIC could not be detected within the E-test
concentration range and would be 64 g/ml.
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mutant (Fig. 1A), are the only antibiotics tested that lack aromatic or hydrophobic
moieties (Fig. S1). To test polar hydrophilic binding sites in BcnA compared to hydro-
phobic sites, we used two related BODIPY dye-labeled phospholipids. BcnA increased
the intensity of ﬂuorescence of the BODIPY ﬂuorophore when attached to the fatty acyl
chain of the phospholipid in BODIPY-phosphocholine but not when attached to the
hydrophilic polar head group (BODIPY-phosphoethanolamine) (Fig. S3R to T). This
further supported a role for fatty acyl chains in the interaction with hydrophobic sites
in BcnA.
Structure determination and molecular modeling reveal distinct docked bind-
ing modes for BcnA. To elucidate the mode of binding of antibiotics within BCNs, we
ﬁrst solved the X-ray crystal structures of BcnA and BcnB to 1.4- and 1.6-Å resolutions,
respectively (Text S1, Table S1, and Fig. S4A to E). Visual inspection and structural
alignments by the DALI server (25) conﬁrmed a barrel-shaped lipocalin fold for both
proteins (Fig. 4A and B). An octaprenyl pyrophosphate was bound within a long,
hydrophobic tunnel extending from one end of the barrel in each structure (Fig. S4A
and B). The binding of octaprenyl pyrophosphate potentially occurred during recom-
binant expression in Escherichia coli. Analysis with the PDBePISA server (26) predicted
that BcnA is a monomer, while BcnB is a dimer, by crystallographic symmetry (~2,840 Å2
of buried surface area including a portion of the tunnel opening). These oligomeric
states were conﬁrmed in solution by size exclusion chromatography-multiangle light
scattering (SEC-MALS; see Fig. S4C and D). Superposition of BcnA chain A and BcnB
chain C (148 C atoms, 22% sequence identity) resulted in a root mean square
deviation (RMSD) of 1.66 Å (Fig. 4C). The largest structural differences observed were
located in two of the loops that make up the tunnel opening (Fig. 4C). These differences
may play a role in the antibiotic binding potential of BcnA and BcnB.
Using the established crystallographic structures, we applied molecular modeling
and docking calculations to predict BCN binding modes of antibiotics (Text S1). These
FIG 3 BCNs bind antibiotics and other molecules hydrophobic in nature with high afﬁnities. (A)
Antibiotic assay showing the mean reduction in the concentration of hydrophobic antibiotics because of
sequestration by BcnA  SEM (n  3 from three independent experiments). *, P  0.05 (determined by
one-sample t test compared to a hypothetical 0% antibiotic sequestration). At the chosen sample size,
the actual power of the assay to detect statistically signiﬁcant effects at a signiﬁcance level (alpha) of
0.05, two tailed, is 99%. ns, not signiﬁcant. (B) In vitro binding assay showing mean binding inhibition
constants (Ki values) of antibiotics against 1.5 M Nile red binding to 1.5 M BcnA in PBS in three
independent experiments (n  5).
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studies suggested two distinct docked binding modes for BcnA. One binding mode
involved residues in the rim of the lipocalin pocket (Fig. 4D; see Fig. S4F to I). Polar
interactions, mainly with polar residues, were observed with all of the antibiotics tested.
There were also interactions between the aromatic moieties in PmB, rifampin, norﬂoxa-
cin, and ceftazidime and lipophilic residues. These interactions were not observed with
gentamicin, which lacks aromatic moieties and binds weakly to BcnA. The second
binding mode was predicted for more lipophilic molecules (e.g., Nile red), occurring
deeper inside the lipophilic tunnel (Fig. 4E). Further, analyses from molecular dynamic
(MD) simulations suggested both structural and ligand recognition roles for residues
D82 and D93 (Text S1). These residues are located in the loops at the top of the tunnel
opening of BcnA. Site-directed mutagenesis was performed, and the BcnAD82A-D93A
mutant showed decreased binding afﬁnity for Nile red (Fig. S5A and B), which we
propose is due to structural changes (Text S1; Fig. S6A to E and S7). Docking of Nile red
into the BcnAD82A-D93A mutant (following the general docking protocol with the
minimized average structure from ns 2.5 to ns 5 of the MD simulation) did not lead to
any binding position inside the lipophilic tunnel (Fig. S7). Interestingly, D93 is a highly
conserved residue in the consensus motif of the BCN protein family (Fig. S5C), exem-
pliﬁed in the alignment of BCN homologues (Fig. S5D). Further, Asp is found in
positions equivalent to D82 in homologues of B. cenocepacia BcnA. Thus, it is credible
that the mode of interaction between BcnA and antibiotics is common among this
large family of conserved bacterial proteins.
Exogenous BcnA protects different bacterial species from antibiotic killing in
vitro and in vivo. Since B. cenocepacia BcnA is secreted (Fig. S2D), as predicted for most
other BCNs, we hypothesized that exogenous BCNs produced by one bacterial species
have the potential to protect other bacteria from the action of antibiotics, including
antimicrobial peptides. This was investigated by using puriﬁed recombinant BCNs from
FIG 4 Structural analysis of BcnA and BcnB and ligand docking modeling. (A) BcnA (blue) is a monomer. (B) BcnB
(protomer 1, chain C, peach; protomer 2, chain D, gray) is a dimer. (C) Superposition of BcnA and BcnB with
dissimilar tunnel opening loops boxed. (D) Docked structure of PmB in complex with the BcnA crystallographic
structure. (E) Docking model presenting the superimposition of the two best predicted binding modes of Nile red
(magenta and cyan) and -tocopherol (yellow) when docked into the BcnA crystallographic structure.
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B. cenocepacia. In vitro antibiotic protection assays showed that P. aeruginosa PAO1
treated with 1.5 M puriﬁed BcnA, but not BcnB, had reduced sensitivity to PmB
(Fig. 5A). In contrast, at 8- to 16-fold lower PmB concentrations, both proteins protected
Salmonella enterica Typhi, Shigella ﬂexneri, Acinetobacter baumannii, Acinetobacter
lwofﬁi, and Acinetobacter junii strains (Fig. S7A). This disparity in the PmB concentrations
at which protection by BcnA and BcnB occurs correlates with their relative afﬁnities to
Nile red (Fig. S3N to Q; see above). In vivo infections of C57BL/6 mice demonstrated that
BcnA protected P. aeruginosa Q502, a virulent cystic ﬁbrosis clinical isolate (27), from
PmB killing in an intraperitoneal (i.p.) sepsis model (Fig. 5B). We also employed the
Galleria mellonella larval infection model. The ΔbcnA and ΔbcnB mutants had reduced
virulence in G. mellonella relative to that of the parent strain (Fig. S7B). However,
signiﬁcantly lower numbers of ΔbcnA mutant bacteria than parental and ΔbcnB mutant
strain bacteria were recovered from the hemolymph of infected larvae at 200 min
postinfection (Fig. S6B), suggesting that ΔbcnA mutant bacteria were more susceptible
FIG 5 B. cenocepacia BcnA protects P. aeruginosa in vitro and in vivo. (A) In vitro protection of
P. aeruginosa PAO1 against PmB with 1.5 M BcnA or BcnB (n  8 from four independent experiments,
plotted as the mean  SEM). PAO1 treated with BcnA is signiﬁcantly different from control PAO1 and
PAO1 plus BcnB at 0.25 g/ml, as determined by two-way ANOVA with an overall P value of 0.001 and
the Bonferroni post hoc test. At the chosen sample size, the actual power of the assay to detect
statistically signiﬁcant effects at a signiﬁcance level (alpha) of 0.05, two tailed, ranged between 95 and
99%. (B) Protection of P. aeruginosa Q502 from PmB killing in an i.p. infection of C57BL/6 mice, plotted
as the median plus the interquartile range. Signiﬁcant differences were determined by the Kruskal-Wallis
test with P  0.001 and Dunn’s multiple-comparison test. At n  6, the actual power of the assay to
detect statistically signiﬁcant effects at a signiﬁcance level (alpha) of 0.05, two tailed, ranged between
control and PmB-treated groups is 99%, and that between PmB and PmB plus BcnA-treated groups is
80%. ns, not signiﬁcant. (C) The survival of G. mellonella larvae infected with P. aeruginosa PAO1
compared to control group injected with sterile PBS; 10 larvae/group; the results were obtained from
three independent experiments and are shown as the mean  SEM. The survival at 24 h of both PAO1-
and PAO1-BcnB-treated larvae is signiﬁcantly different from that of the PAO1-BcnA-treated group at P 
0.001 (determined by two-way ANOVA with an overall P value of 0.001 and the Bonferroni post hoc
test). At the chosen sample size, the actual power of the assay to detect statistically signiﬁcant effects at
a signiﬁcance level (alpha) of 0.05, two tailed, is 90%. (D) Numbers of PAO1 CFU per milliliter recovered
from larval hemolymph at 200 min postinfection (n  10 from two independent experiments shown as
the mean  SEM). **, P  0.01 (one-way ANOVA with an overall P value of 0.006 and the Bonferroni post
hoc test). At the chosen sample size, the actual power of the assay to detect statistically signiﬁcant effects
at a signiﬁcance level (alpha) of 0.05, two tailed, is 99% in the case of BcnA versus BcnB-treated PAO1
and 85% in the case of BcnA-treated versus control PAO1.
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than ΔbcnB mutant bacteria to the larval humoral immune response, which is mainly
driven by host antimicrobial peptides (28, 29), mirroring the different in vitro suscep-
tibilities of ΔbcnA and ΔbcnB mutant bacteria to PmB. Similarly, infection of BcnA-
treated G. mellonella larvae with P. aeruginosa PAO1 resulted in more rapid killing of the
larvae than control or BcnB-treated larvae (Fig. 5C). We recovered signiﬁcantly higher
numbers of bacterial CFU from the hemolymph of BcnA-treated infected larvae
(Fig. 5D), suggesting that exogenous BcnA gives infecting bacteria a survival advantage.
Enhanced bacterial killing of BcnA-treated larvae was also observed for Klebsiella
pneumoniae, A. baumannii, and S. aureus USA300 (Fig. S7C). Together, the in vivo
infection results underpin a biological role for BCNs in giving infecting bacteria of
different species a survival advantage.
Liposoluble vitamins inhibit BcnA-mediated antibiotic capture. Conceivably,
molecules with superior binding afﬁnity for BCNs than that of antibiotics should
prevent BCN-mediated resistance. Since lipophilic moieties are predicted to bind deep
within the BCN pocket, we tested normal dietary hydrophobic supplements recom-
mended for several patient groups, including cystic ﬁbrosis patients, such as the
fat-soluble vitamins -tocopherol (vitamin E) and menaquinone (vitamin K2). Docking
of -tocopherol showed its alkyl chain buried in the BcnA tunnel and its cyclic head
placed toward the entrance, similar to the Nile red binding pose (Fig. 4E). Of note,
-tocopherol, followed by menaquinone, exhibited very low Ki values in Nile red
displacement assays (~2 to 4 orders of magnitude lower than the Ki values of antibi-
otics), indicative of their high afﬁnity for BcnA (Fig. 3B). This prompted us to test the
BCN-inhibitory activity of fat-soluble vitamins in vivo. In BcnA-treated G. mellonella
larvae infected with P. aeruginosa PAO1, 10 M -tocopherol or menaquinone signif-
icantly reduced the survival advantage of P. aeruginosa (Fig. 6A). This supports the
notion that the protective function of BCN in infecting bacteria can be inhibited in vivo
(Fig. 6B).
FIG 6 Fat-soluble vitamins inhibit BCN-mediated antibiotic binding. (A) The survival of G. mellonella
larvae at 20 h postinfection in an in vivo assay of P. aeruginosa PAO1 protection by 1.5 M BcnA in the
presence or absence of 10 M -tocopherol (vitamin E) or menaquinone (vitamin K2) with 10 larvae per
group. The results were obtained from four independent experiments and are shown as the mean
percentage of larval survival in each experiment  the SEM. The larval survival of all of the groups was
100% at zero time and 0% at 44 h, with the exception of the PBS-treated control group, which remained
100%. *, P  0.05; **, P  0.01; ***, P  0.001 (determined by two-way ANOVA with an overall P value
of 0.001 and the Bonferroni post hoc test). At the chosen sample size, the actual power of the assay to
detect statistically signiﬁcant effects at a signiﬁcance level (alpha) of 0.05, two tailed, is 95%. ns, not
signiﬁcant. (B) Model of the mechanism of resistance by BcnA (top) and its inhibition by the fat-soluble
vitamins (bottom).
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DISCUSSION
Lipocalins are an ancient family of small proteins found in all kingdoms of life that
have the ability to bind hydrophobic ligands but have different functions, depending
on the cell types and organisms (30, 31). In many cases, and particularly in bacteria (18),
their function is unclear despite that BCN orthologs can be found in the majority of
completed genomes by data mining. In this study, we discovered that secreted BCNs
contribute to antibiotic resistance by capturing and neutralizing antibiotics in the
bacterial milieu. BCNs bind a range of antibiotics with diverse chemical structures,
increasing antibiotic resistance in vitro and enhancing bacterial survival in vivo. The
effect of BCNs on multiple antibiotics and their wide conservation in most bacterial
species distinguish this mechanism from the recently discovered effect of membrane-
released phospholipids on daptomycin (14), which is restricted to this particular
antibiotic and to S. aureus.
Our structural work suggests that BCNs have two binding modes. Hydrophobic
molecules like Nile red and vitamins E and K2 can bind in the interior of the lipocalin
tunnel, while antibiotic molecules interact with the rim and their binding properties are
much weaker. This suggests that antibiotic binding and scavenging are not primary
functions of secreted BCNs, but these proteins may also have other, as-yet-
undiscovered, roles. We propose that the antibiotic binding ability of BCNs becomes
particularly relevant under conditions in which antibiotics cannot effectively kill bac-
teria and their presence at sublethal concentrations elicits protective bacterial stress
responses. Exposure to antibiotics triggers complex and multifactorial bacterial pro-
cesses involving changes in regulation, metabolism, and energy generation (32–36).
There is also a body of evidence indicating that antibiotics at sublethal concentra-
tions can stimulate the production of reactive oxygen intermediates (37–41) and also
that oxidative stress associated with pathological inﬂammation reduces the efﬁcacy of
antibiotics (34). The increased bcnA transcription upon antibiotic treatment indicates
that this gene responds to antibiotic-induced stress. Recent work with the model plant
Arabidopsis thaliana shows that two lipocalins that are related to bacterial orthologs
have distinct but overlapping functions essential for protection from lipid peroxidation
(42). Further, the mammalian odorant-binding protein, a soluble lipocalin, protected
the bacterial cells from hydrogen peroxide-induced stress when overexpressed in E. coli
(43), whereas P. aeruginosa PAO1 BcnA1(Pa) was overexpressed in response to hydro-
gen peroxide and paraquat (44). Donnarumma et al. (19) have recently suggested that
the Neisseria BCN (GNA1030) is a ubiquinone-8 binding protein. Since ubiquinone-8 is
a cofactor that is mainly involved in the electron transport chain (45) and has antiox-
idant properties (46), these authors propose a role for this protein in antioxidant
defense, perhaps by delivering ubiquinone-8 to the bacterial membrane or the
periplasmic space. Ubiquinones are prenylated benzoquinones. Interestingly, the ma-
jority of known crystal structures of bacterial lipocalins, including BcnA and BcnB, have
been solved with octaprenyl-like molecules bound to the lipocalin tunnel, although it
is not certain if the presence of this molecule corresponds to a physiological substrate
or is an artifact associated with protein puriﬁcation prior to crystallization. Therefore,
while it may be reasonable to propose that BCNs could play a role in oxidative stress
responses, the mechanisms involved remain to be elucidated.
In summary, we have uncovered a new mechanism of general antibiotic resistance
operating extracellularly based on BCN-mediated antibiotic capture that provides
bacteria with a selective advantage to overcome antibiotic toxicity, particularly in
chronic infections, where antibiotic treatment often fails. Further, we reveal a strategy
to disrupt antibiotic capture and propose liposoluble vitamins as clinically usable BCN
inhibitors.
MATERIALS AND METHODS
Strains and reagents. Table S2 lists the bacteria and plasmids used in this study. Bacteria were
grown in LB broth, supplemented with 0.4% rhamnose when required at 37°C. E. coli cultures were
supplemented as required with the antibiotics (ﬁnal concentrations) tetracycline (30 g/ml), kanamycin
(40 g/ml), and trimethoprim (50 g/ml). B. cenocepacia cultures were supplemented as required with
Extracellular Antibiotic Capture by Bacteria ®
March/April 2017 Volume 8 Issue 2 e00225-17 mbio.asm.org 9
 
m
bio.asm
.org
 o
n
 M
arch 24, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
trimethoprim (100 g/ml) and tetracycline (100 g/ml). Antibiotics (Sigma) were diluted in water, except
for PmB, which was diluted in 0.2% bovine serum albumin–0.01% glacial acetic acid buffer. Rifampin was
dissolved in dimethyl sulfoxide (DMSO).
General molecular techniques. DNA manipulations were performed as previously described (47). T4
DNA ligase (Roche Diagnostics), Antarctic phosphatase (New England Biolabs), and restriction endonu-
cleases were used as recommended by the manufacturers. Transformation of E. coli GT115 and DH5 was
performed by the calcium chloride method (48). Mobilization of plasmids into B. cenocepacia was
conducted by triparental mating (49) with E. coli DH5 carrying the helper plasmid pRK2013 (50). DNA
ampliﬁcation by PCR was performed with a C1000 thermal cycler (Bio-Rad Laboratories Ltd., Mississauga,
Ontario, Canada) using Taq or HotStar HiFidelity DNA polymerase (Qiagen) and optimized for each primer
pair. DNA sequencing was carried out at Euroﬁns, Huntsville, AL. The DNA sequences were analyzed with
the BLAST computer program and compared to the sequenced genome of B. cenocepacia strain J2315.
The sequence of S. aureus gene SAUSA300_2620 was optimized for B. cenocepacia codon usage and
custom synthesized at Euroﬁns. Cloning, expression, and puriﬁcation of bacteriocalins were performed as
previously described (17). Transcriptional fusions to luxCDABE and the subsequent luminescence expres-
sion assays were performed as previously described (37). For site-directed mutagenesis, pOE16 was
ampliﬁed with Pfu polymerase and the appropriate primer pairs; the PCR products were digested
overnight with 1 U of DpnI at 37°C and then introduced into E. coli DH5 competent cells by
transformation. Transformants were selected on LB agar plates supplemented with kanamycin; amino
acid replacements were conﬁrmed by DNA sequencing.
Protein analysis and Western blotting. Overnight cultures were diluted to an optical density at 600
nm (OD600) of 0.03 in 30 ml of fresh LB medium with or without PmB and incubated for 3.5 h at 37°C at
200 rpm. Following incubation, cells equivalent to an OD600 of ~0.2 were pelleted, resuspended in 30 l
of SDS-PAGE protein loading dye, and boiled to obtain whole-cell lysates. Secreted proteins were
precipitated from the supernatant of the rest of the cultures with 10% trichloroacetic acid as previously
described (51). Precipitated proteins were resuspended in Tris buffer at 1 M and pH 7.5. The volume of
protein samples loaded onto the 16% SDS-polyacrylamide gel was normalized to the OD600 value. After
SDS-PAGE, proteins were transferred onto nitrocellulose membranes and the membranes were blocked
overnight at 4°C with Western blocking reagent (Roche Diagnostics, Laval, QC, Canada) in TBST (50 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% Tween 20). The primary antibody, anti-FLAG M2 monoclonal
antibody (Sigma) or anti--subunit RNA polymerase (E. coli) (Neoclone, Madison, WI), was diluted to
1:15,000 in TBST and applied for 1.5 h. The secondary antibody, goat anti-mouse Alexa Fluor 680 IgG
antibody (Invitrogen), was diluted to 1:15,000 and applied for 1 h. Western blot assays were developed
with the LI-COR Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE).
Antibiotic susceptibility testing. The inoculum of B. cenocepacia K56-2, the appropriate mutants,
and other bacterial species was prepared by the direct colony suspension method according to CLSI (52).
Cultures with an OD600 of 0.0008 in fresh cation-adjusted Mueller-Hinton broth (MHB) with or without the
antibiotic were incubated at 37°C with medium shaking continuously in a Bioscreen C automated growth
curve analyzer (MTX Lab Systems, Vienna, VA). Bacterial growth was assessed turbidimetrically at 600 nm.
E-test strips (AB BioMérieux, Solna, Sweden) were applied to agar plates (17 ml of agar in an 85-mm petri
dish) inoculated with test bacteria by swabbing overnight cultures diluted to an OD600 of 0.04; plates
were then incubated at 37°C for 24 h. Alternatively, population proﬁling analysis was performed
turbidimetrically or by CFU counting as previously described (17). For in vitro protection assays,
B. cenocepacia bacteriocalins were added to LB broth at a ﬁnal concentration of 1.5 M.
In vitro binding assays. In vitro binding assays were performed as previously described (23), with
a few modiﬁcations. Puriﬁed BCNs were prepared in phosphate-buffered saline (PBS, pH 7.4). Phospho-
lipids and Nile red were prepared in DMSO. The binding of each ﬂuorescent probe to BCNs was measured
by titrating 100 l of BCNs (1.5 M) in a ﬂat-bottom 96-well microtiter plate (LUMITRAC 200 White;
Greiner Bio-One, Monroe, NC) with aliquots of increasing concentrations of probe until the ﬂuorescence
intensity reached a plateau, indicating that all of the binding sites were occupied. All spectra were
corrected for background ﬂuorescence determined from probe-into-buffer titrations. Fluorescence was
measured with a Cary Eclipse ﬂuorescence spectrophotometer (Varian) set at an excitation wavelength
(ex) speciﬁc for each probe, as follows: Nile red, 550 nm; BODIPY phospholipids, 500 nm for fatty acyl
BODIPY-labeled phosphocholine and 505 nm for head group BODIPY-labeled phosphoethanolamine.
The emission spectrum for each probe was collected across the following wavelengths (em): Nile red,
590 to 750 nm; BODIPY phospholipids, 510 to 665 nm. The background-corrected binding ﬂuorescence
with each probe was ﬁtted to a one-site binding model as previously described for human AGP (23). The
equilibrium binding afﬁnity constant for the probe-BCN complex (Kd), the probe concentration needed
to achieve half-maximum binding at equilibrium, was determined by nonlinear least-squares regression
analysis of the binding isotherms with GraphPad Prism v 5.0 software (GraphPad Software, Inc.).
For probe displacement experiments, antibiotic solutions and fat-soluble vitamins (prepared in
DMSO) diluted in PBS, pH 7.4, were titrated against a BCN-probe complex at a saturating concentration
necessary to obtain the maximum ﬂuorescence when bound. Probe displacement was measured as the
corresponding decrease in ﬂuorescence upon the progressive increase in the antibiotic concentration.
The binding inhibition constants (Kis) of the test compounds were determined by nonlinear regression
analysis with competition-binding equations for one-site binding calculated by GraphPad Prism v 5.0
software. The lower the Ki values, the higher the afﬁnity of the molecule for BcnA. All ﬂuorometric assays
were conducted in duplicate three independent times.
G. mellonella larva in vivo infection. Larval infection assays were performed as previously described
(53), with modiﬁcations. Overnight cultures were diluted in PBS, pH 7.4, with or without B. cenocepacia
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BCNs at a 1.5 M ﬁnal concentration to the following OD600s: B. cenocepacia and P. aeruginosa PAO1,
0.00004; K. pneumoniae Kpn18, 0.04; A. baumannii AB1, 0.4; S. aureus USA300, 0.004. The larvae were
injected with 10 l of the bacterial suspensions or sterile PBS (10 larvae/group in each experiment) with
10-l MICROLITER syringes (Hamilton). The larvae were incubated at 30°C, and their viability was checked
at regular time intervals. In similar assays, ﬁve larvae/group were sacriﬁced at 200 min postinfection and
the hemolymph was extracted as previously described (53). The hemolymph was immediately serially
diluted in PBS and plated on LB agar supplemented with 0.3% cetrimide or 200 g/ml ampicillin–
25 g/ml PmB to quantify the CFU of P. aeruginosa PAO1 or B. cenocepacia, respectively, recovered from
the infected larvae.
Intraperitoneal infection of mice. A clinical isolate of P. aeruginosa (strain Q502) was grown
overnight in nutrient broth at 37°C with constant agitation. The bacteria were centrifuged at 2,000  g
and washed three times in sterile, endotoxin-free PBS. The bacteria were resuspended in sterile,
injection-grade saline, and the inoculum was adjusted to an OD of 0.5 (A550). Female adult (8- to
12-week-old) C57BL6 mice were infected i.p. with 100 l of the bacterial suspension. Subsequent growth
of the inoculum on nutrient agar demonstrated that each animal received 106 CFU. Six mice per
treatment were used. This was determined by GraphPad StatMate 2.0 to ensure 80% power to detect
statistically signiﬁcant effects between antibiotic-treated and untreated animals at a signiﬁcance level
(alpha) of 0.05, two tailed. The actual power was 99%. Mice were selected at random from open stock
cages (10 per cage), earmarked to allow individual identiﬁcation, and then sequentially placed into
treatment groups. During the course of the experiment, mice were housed in individually ventilated
cages. This method of assigning animals to groups ensures an approximately equal distribution of mice
from different stock cages in each group to minimize the inﬂuence of cage-to-cage variability. At the time
of inoculation, the mice were treated with the standard pediatric PmB dose of 20,000 U/kg (n  6), PmB
and 100 l of 25 M BCN (n  6), BCN only (n  6), or a saline control (n  6) by i.p. injection. The
individual components injected into mice were added to the same syringe immediately before i.p.
injection. Animals were culled by cervical dislocation 4 h postinoculation. That time point was selected
because by that time point and under the infection conditions used, the untreated mice reach the
humane endpoint and need to be culled, as deﬁned within the UK Home Ofﬁce license under which the
experiments were carried out (PLL 2700). Because of the virulence of the clinical isolate and the dose of
the bacterial inoculum and because the bacteria are delivered i.p., the mice rapidly succumb to the
infection. In contrast, those given effective antibiotic treatment rapidly clear the infection and remain
perfectly healthy. The vast divergence between the responses seen in this model provides us with the
statistical power to robustly assess the microbial response to antibiotic therapies without requiring the
use of a very large number of mice per group. We are therefore adhering to the reduction principle of
the three R’s. The peritoneal cavity was lavaged with 3.5 ml of ice-cold, sterile, endotoxin-free PBS, and
the volume recovered was recorded. Serial dilutions of the lavage ﬂuid were plated onto cetrimide agar;
and bacterial colonies were counted after 24 h of growth at 37°C. Harvesting of the samples and
quantiﬁcation of the bacterial burdens in the mice were done while blinded to the treatment groups.
Data were not normally distributed, and there was no equal variance between groups; therefore, a
nonparametric Kruskal-Wallis test was used. The mouse infection experiments carried out were assessed
by the Queen’s University Belfast animal welfare and ethical review body (AWERB) committee and
conducted under a license issued by the UK Home Ofﬁce under the Animals (Scientiﬁc Procedures) Act
1986, amended in 2012.
Antibiotic bioassay. Antibiotic test solutions with or without 1.5 M BcnA were incubated for
30 min at 37°C with rotation. The solutions were ﬁltered through ﬁlter units with a 10-kDa cutoff by
centrifugation at 7,500  g, at 4°C for 10 min. The antibiotic concentrations in the ﬁltrates were
determined by spotting 5 l onto sterile ﬁlter discs placed on agar plates swabbed with the test bacteria.
Petri dishes (15-cm diameter) containing 40 ml of LB agar were swabbed with bacterial suspensions with
an OD600 of 0.04. The plates were incubated at 37°C for 24 h. Each plate included four discs containing
standard concentrations of the antibiotic alongside the discs impregnated with test and control
antibiotic solutions. E. coli DH5 was used for bioassays of PmB, norﬂoxacin, ceftazidime, and gentamicin,
and S. aureus USA300 was used for bioassays of rifampin. The theoretical disc contents of the test
antibiotic solutions were 10, 5, 2, 30, and 10 g for PmB, rifampin, norﬂoxacin, ceftazidime, and
gentamicin, respectively. Standard antibiotic discs contained a 2-fold higher concentration than, the
same concentration as, or a 2- or 4-fold lower concentration than the test antibiotic discs. After
incubation, the clear zones of inhibition were measured and the antibiotic concentrations were deter-
mined from standard curves constructed from the standard antibiotic discs.
Structure determination. BcnA and BcnB were puriﬁed by fast protein liquid chromatography and
concentrated to ~20 mg/ml in a mixture of 20 mM Tris (pH 7.5) and 100 mM NaCl (1% DMSO for BcnB)
with95% purity. Protein solutions were mixed 1:1 with mother liquor, and crystals were grown at room
temperature. BcnA crystals grew with 0.1 M Tris (pH 8.5) and 2.4 M ammonium sulfate (ﬁnal pH of 8.0)
as the mother liquor. BcnB crystals grew with 0.1 M HEPES (pH 6.5)–26% polyethylene glycol 6000 as the
mother liquor. Data sets were collected on beamline 08ID-1 at Canadian Light Sources (54), integrated
with iMOSFLM (55), and scaled with AIMLESS (56) from CCP4. Phases for BcnA and BcnB were obtained
with Phaser.MRage (57) from PHENIX with PDB accession no. 2FGS and 1WUB, respectively, as the search
models. Both structures were initially built with AutoBuild (58) from PHENIX and then manually built with
Coot (59). The BcnA and BcnB structures were reﬁned with phenix.Reﬁne (60) from PHENIX and REFMAC5
(61) from CCP4, respectively, with translation-libration-screw motion reﬁnement for both. Figures were
generated with Pymol, version 1.8 (https://www.pymol.org/). Data collection and reﬁnement statistics are
provided in Table S1 in the supplemental material. SEC-MALS experiments were conducted to assess the
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oligomeric solution state of BcnA and BcnB as previously described (62) with proteins diluted to 1 mg/ml
in 20 mM Tris (pH 7.5)–100 mM NaCl.
Computational methods. All of the following codes can be obtained under license agreement:
AMBER 12 and AmberTools (http://www.ambermd.org), Maestro Suite (Schrödinger, Cambridge, MA),
AutoDock 4.2.2, and AutoDockTools (http://autodock.scripps.edu; free software). Amber and Maestro
have Academic fees. We studied the stability of the two X-ray structures of BcnA and BcnB, as well as the
D82A-D93A mutant, by MD simulations as implemented in AMBER 12. The initial model of D82A-D93A
was built with AmberTools. Missing hydrogen atoms were added, and the protonation state of ionizable
groups was computed by using Maestro Protein Preparation Wizard, version 9.3 (Schrödinger, Cam-
bridge, MA). Atom types and charges were assigned according to AMBER ff10 force ﬁeld (63). The three
molecular systems were hydrated by using cubic boxes containing explicit TIP3P water molecules
extending 10 Å away from any protein atom for simulating the aqueous environment with the help of
AmberTools with added counterions to neutralize the system. Before the MD simulations, the two
systems were equilibrated under the following protocol: an initial 8,000 steps of steepest-descent
minimization, followed by heating of the system with position restraint (force constant of 20 kcal mol1
Å2) for all protein atoms during 10 ps of MD simulation increasing the temperature from 100 K to 300 K
plus an additional 15 ps at a constant temperature of 300 K. Position restraint was gradually decreased
for 100 ps at a constant 300 K, until the full system was under no restraint with constant temperature
(300 K) and pressure (1 atm). After equilibration, 20 ns of MD simulation was run at a constant
temperature (300 K) and pressure (1 atm). Short- and long-range forces were calculated every one and
two time steps, respectively (each time step was 2.0 fs), constraining the covalent bonds involving
hydrogen atoms to their equilibrium values. Long-range electrostatic interactions were accounted for by
means of the particle mesh Ewald approach applying periodic boundary conditions. The RMSD as a
function of time with respect to the starting structure of the -C atoms was computed with CPPTRAJ (64).
The three-dimensional (3D) coordinates of the structures of BcnA and BcnB subjected to the equilibration
protocol described above were used for docking purposes. The two models were prepared for docking
calculations by adding Kollman charges (65) with the help of AutoDockTools.
3D coordinates of norﬂoxacin, PmB, ceftazidime, gentamicin, Nile red, and -tocopherol were built
in Corina (66) from the SMILES code. The 3D structure of rifampin was extracted from the crystallographic
structure PDB accession no. 1LSV. The structures of the seven ligands were protonated at pH 7.0 with
Epik (67) and then optimized with MMFFs force ﬁeld by with MacroModel version 9.9 (Schrödinger,
Cambridge, MA). Additionally, the structure of PmB was subjected to 100 ps of MD simulation at 300 K.
Ligands were prepared for docking calculations with AutoDockTools by adding Gasteiger charges (68)
and setting all rotatable bonds free to move during the docking calculation.
Docking calculations of all compounds were performed by means of AutoDock 4.2.2 (69). Analysis
was performed with the help of AutoDockTools. The grid point spacing was set at 0.375 angstroms, and
a hexahedral box was built with x, y, and z dimensions of 21.00, 26.25, and 27.75 angstroms centered in
the binding site of the protein. Two hundred runs with the Lamarckian genetic algorithm were
performed with a population size of 100 and 250,000 energy evaluations. Side chains of residues Y85,
W94, and Q41 were considered ﬂexible during the docking protocol.
BCN consensus motif determination. A subset of 187 curated BcnA homologues from different
bacterial species and families were used to obtain a consensus motif generated by the Gapped Local
Alignment Motifs GLAM2 tool (70). This motif was veriﬁed by analyzing an alignment of 1,995 BCN
homologues with CLUSTAL-omega and visualized with JalView. In addition, upon submitting the
predicted motif to the GLAM2Scan database (70) against B. cenocepacia, P. aeruginosa PAO1, M. tuber-
culosis H37Rv, and S. aureus USA300, the correct homologues only were detected as BCNs for each of the
organisms.
Statistical analyses. Statistical analyses were conducted with GraphPad Prism 5.0. All of the results
shown are the mean  the standard error of the mean (SEM) unless otherwise stated. Unless otherwise
stated, data were assumed to follow a Gaussian distribution as determined by the D’Agostino-Pearson
omnibus K2 normality test whenever possible, and hence, t tests and analysis of variance (ANOVA) were
used. An unpaired t test was used to compare the means of two unmatched groups. A paired t test was
used to compare the means of two matched groups, assuming that the before-and-after differences
follow a Gaussian distribution. The sample size was chosen with GraphPad StatMate 2.0 to ensure a
minimum of 80% power to detect statistically signiﬁcant effects at a signiﬁcance level (alpha) of 0.05, two
tailed. However, the actual power of most of the assays was 90% and in many cases exceeded 99%. In
the case of MIC assays, the experiments were repeated three independent times and the experiment
showing the lowest fold change (if applicable) was reported.
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